References
- Attarian, S., Vallat, J.-M., Magy, L., Funalot, B., Gonnaud, P.-M., Lacour, A., Péréon, Y., Dubourg, O., Pouget, J., Micallef, J., et al. (2014). An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1A. Orphanet J. Rare Dis., 9, 199.10.1186/s13023-014-0199-0431141125519680
- Azevedo, H., Pupe, C., Pereira, R., Nascimento, O. (2018). Pain in Charcot-Marie-Tooth disease: An update. Arquivos de Neuro-Psiquiatria, 76, 273–276.10.1590/0004-282x2018002129742248
- Bacquet, J., Stojkovic, T., Boyer, A., Martini, N., Audic, F., Chabrol, B., Salort-Campana, E., Delmont, E., Desvignes, J.-P., Verschueren, A., et al. (2018). Molecular diagnosis of inherited peripheral neuropathies by targeted next-generation sequencing: Molecular spectrum delineation. BMJ Open, 8 (10), e021632–e021632.10.1136/bmjopen-2018-021632622471430373780
- Bird, T. D. (2019). Charcot-Marie-Tooth (CMT) Hereditary Neuropathy Overview 1. Clinical Characteristics of Charcot-Marie-Tooth (CMT) Hereditary Neuropathy. GeneReviews, 1–22. https://www.ncbi.nlm.nih.gov/books/NBK1358/ (accessed 12.03.2022).
- Bjelica, B., Peric, S., Basta, I., Bozovic, I., Kacar, A., Marjanovic, A., Ivanovic, V., Brankovic, M., Jankovic, M., Novakovic, I., et al. (2020). Neuropathic pain in patients with Charcot-Marie-Tooth type 1A. Neurological Sciences, 41 (3), 625–630.10.1007/s10072-019-04142-531729581
- Chanson, J.-B., Echaniz-Laguna, A., Blanc, F., Lacour, A., Ballonzoli, L., Kremer, S., Namer, I.-J., Lannes, B., Tranchant, C., Vermersch, P., et al. (2013). Central nervous system abnormalities in patients with PMP22 gene mutations: A prospective study. J. Neurol. Neurosurg. Psychiatry, 84 (4), 392–397.10.1136/jnnp-2012-30372523243264
- Cornett, K. M. D., Menezes, M. P., Bray, P., Halaki, M., Shy, R. R., Yum, S. W., Estilow, T., Moroni, I., Foscan, M., Pagliano, et al. (2016). Phenotypic variability of childhood Charcot-Marie-Tooth disease. JAMA Neurology, 73 (6), 645–651.10.1001/jamaneurol.2016.0171491686127043305
- Corrado, B., Ciardi, G., Bargigli, C. (2016). Rehabilitation management of the Charcot-Marie-Tooth Syndrome: A systematic review of the literature. Medicine, 95 (17), e3278–e3278.10.1097/MD.0000000000003278499868027124017
- Daniel, A., G.-E., Carmen, C.-R., Guillermo, O.-A. (2019). Charcot-Marie-Tooth disease Type 1A and inflammatory-demyelinating lesions in the central nervous system. Int. J. Neurol. Neurother., 6 (1), 1–4.10.23937/2378-3001/1410080
- Fridman, V., Bundy, B., Reilly, M. M., Pareyson, D., Bacon, C., Burns, J., Day, J., Feely, S., Finkel, R. S., Grider, et al. (2015). CMT subtypes and disease burden in patients enrolled in the Inherited Neuropathies Consortium natural history study: A cross-sectional analysis. J. Neurol. Neurosurg. Psychiatry, 86 (8), 873–878.10.1136/jnnp-2014-308826451600225430934
- Jeong, N. Y., Shin, Y. H., Jung, J. (2013). Neuropathic pain in hereditary peripheral neuropathy. J. Exercise Rehabil., 9 (4), 397–399.10.12965/jer.130057383654624278891
- Johnson, N. E., Heatwole, C. R., Dilek, N., Sowden, J., Kirk, C. A., Shereff, D., Shy, M. E., Herrmann, D. N. (2014). Quality-of-life in Charcot Marie Tooth disease: The patient’s perspective. Neuromusc. Disord., 24 (11), 1018–1023.10.1016/j.nmd.2014.06.433425387125092060
- Kenis-Coskun, O., Matthews, D. J. (2016). Rehabilitation issues in Charcot-Marie-Tooth disease. J. Pediatric Rehab. Med., 9 (1), 31–34.10.3233/PRM-16035926966798
- Kovale, S., Terauda, R., Millere, E., Taurina, G., Murmane, D., Isakova, J., Kenina, V., Gailite, L. (2021). GJB1 gene analysis in two extended families with X-linked Charcot-Marie-Tooth disease. Case Rep. Neurol., 13 (2), 422–428.10.1159/000515170829937834326750
- Millere, A., Kalnberza-Ribule, Z., Mezals, M., Nulle, A., Millere, I., Deklava, L. (2020). Disability, pain catastrophizing and stress coping of patients with low back pain in rehabilitation practice in Latvia. J. Back Musculoskel. Rehab., 33 (2), 323–328.10.3233/BMR-17094531524136
- Millere, E., Gribuste, L., Kazaine, I., Strautmanis, J., Gailite, L., Kenina, V. (2020). Clinical and neurophysiological spectrum of polyneuropathies in children. Neurologia i Neurochirurgia Polska, 54 (5), 466–470.10.5603/PJNNS.a2020.006832939748
- Millere, E., Kupats, E., Mičule, I., Kazaine, I., Rots, D., Gailīte, L., Šterna, O., Kurjāne, N., Ķēniņa, V. (2019). Neuropathic pain in hereditary peripheral neuropathy: Correlation with clinical, genetic and neurophysiological findings. RSU Research Week Abstract Book 2019, 285. https://conference2019.rsu.lv/sites/default/files/documents/knowledge_for_use_in_practice_abstracts_rev.pdf (accessed 19.03.2022).
- Millere, E., Rots, D., Simrén, J., Ashton, N. J., Kupats, E., Micule, I., Priedite, V., Kurjane, N., Blennow, K., Gailite, L., et al. (2021). Plasma neurofilament light chain as a potential biomarker in Charcot-Marie-Tooth disease. Eur. J. Neurol., 28 (3), 974–981.10.1111/ene.1468933340200
- Murphy, S. M., Herrmann, D. N., McDermott, M. P., Scherer, S. S., Shy, M. E., Reilly, M. M., Pareyson, D. (2011). Reliability of the CMT neuropathy score (second version) in Charcot-Marie-Tooth disease. J. Peripheral Nervous Syst., 16 (3), 191–198.10.1111/j.1529-8027.2011.00350.x375482822003934
- Padilha, J. P. D., Brasil, C. S., Hoefel, A. M. L., Winckler, P. B., Donis, K. C., Brusius-Facchin, A. C., Saute, J. A. M. (2020). Diagnostic yield of targeted sequential and massive panel approaches for inherited neuropathies. Clin. Genet., 98 (2), 185–190.10.1111/cge.1379332506583
- Ramchandren, S. (2017). Charcot-Marie-Tooth disease and other genetic polyneuropathies. Continuum (Minneapolis, Minn.), 23 (5, Peripheral Nerve and Motor Neuron Disorders), 1360–1377.10.1212/CON.000000000000052928968366
- Reuter, C. M., Kohler, J. N., Bonner, D., Zastrow, D., Fernandez, L., Dries, A., Marwaha, S., Davidson, J., Brokamp, E., Herzog, M., et al. (2019). Yield of whole exome sequencing in undiagnosed patients facing insurance coverage barriers to genetic testing. J. Gen. Counsel., 28 (6), 1107–1118.10.1002/jgc4.1161690172331478310
- Richards, S., Aziz, N., Bale, S., Bick, D., Das, S., Gastier-Foster, J., Grody, W. W., Hegde, M., Lyon, E., Spector, E., et al. (2015). Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genetics Med., 17 (5), 405–424.10.1038/gim.2015.30454475325741868
- Rossor, A. M., Shy, M. E., Reilly, M. M. (2020). Are we prepared for clinical trials in Charcot-Marie-Tooth disease? Brain Res., 1729, 146625.10.1016/j.brainres.2019.146625
- Rudnik-Schöneborn, S., Tölle, D., Senderek, J., Eggermann, K., Elbracht, M., Kornak, U., von der Hagen, M., Kirschner, J., Leube, B., Müller-Felber, et al. (2016). Diagnostic algorithms in Charcot-Marie-Tooth neuropathies: Experiences from a German genetic laboratory on the basis of 1206 index patients. Clin. Genet., 89 (1), 34–43.10.1111/cge.1259425850958
- Tao, F., Beecham, G. W., Rebelo, A. P., Blanton, S. H., Moran, J. J., Lopez-Anido, C., Svaren, J., Abreu, L., Rizzo, D., Kirk, C. A., et al. (2019). Modifier gene candidates in Charcot-Marie-Tooth disease Type 1A: A case-only genome-wide association study. J. Neuromusc. Dis., 6 (2), 201–211.10.3233/JND-190377659797430958311
- Theadom, A., Roxburgh, R., MacAulay, E., O’Grady, G., Burns, J., Parmar, P., Jones, K., Rodrigues, M., Group, I. C. M. T. R. (2019). Prevalence of Charcot-Marie-Tooth disease across the lifespan: A population-based epidemiological study. BMJ Open, 9 (6), e029240–e029240.10.1136/bmjopen-2019-029240658583831203252
- Tian, D., Zhao, Y., Zhu, R., Li, Q., Liu, X. (2021). Systematic review of CMTX1 patients with episodic neurological dysfunction. Ann. Clin. Translat. Neurol., 8 (1), 213–223.10.1002/acn3.51271781827833314704
- Woo, A. K. (2010). Depression and anxiety in pain. Rev. Pain, 4 (1), 8–12.10.1177/204946371000400103459005926527193